Source-grounded facts extracted from Wellgistics Health, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Wellgistics Health, Inc.: Certificate of Amendment to effect a 1-for-50 reverse stock split of common stock (effective 2025-05-26).
“On May 20, 2025, the Company filed with the Secretary of State of the State of Delaware the Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) to effect the Reverse Stock Split.”
Gerald Commissiong was appointed as Interim Co-Chief Executive Officer at Wellgistics Health, Inc..
“On May 20, 2026, in connection with the Term Sheet described in Item 1.01 of this Current Report on Form 8-K, the Board of Directors of Wellgistics Health, Inc. (the “Company”) appointed Gerald Commissiong as Interim Co-Chief Executive Officer of the Company, effective immediately.”
Wellgistics Health, Inc. entered into Forbearance Agreement with Marco Capital, Inc. valued at approximately $1.77 million (effective 2026-05-01).
“On May 1, 2026, Wellgistics, LLC (“Wellgistics”), a wholly owned subsidiary of Wellgistics Health, Inc. (the “Company”), entered into an Acknowledgment of Indebtedness, Forbearance and Repayment Agreement (the “Forbearance Agreement”) with Marco Capital, Inc. (“MCI”).”
Wellgistics Health, Inc. amended Amended Settlement Agreement with Silverback Capital Corporation (effective 2026-02-09).
“On February 9, 2026, Wellgistics Health, Inc. (the “Company”) entered into an Amended Settlement Agreement (the “Amended Settlement Agreement”) with Silverback Capital Corporation, which amended that certain Settlement Agreement previously referenced in the Original Report (the “Original Settlement Agreement”).”
Wellgistics Health, Inc. entered into Collaboration Agreement with Kare Rx Hub, LLC, Kare Pharmtech, LLC, and Healthstar Technologies, LLC valued at $2,000,000 (effective 2026-04-13).
“On April 13, 2026, Wellgistics Health, Inc. (the “Company”) entered into a Collaboration Agreement (the “Collaboration Agreement”) with Kare Rx Hub, LLC (“Kare Hub”), Kare Pharmtech, LLC (“Kare Pharmtech”), and Healthstar Technologies, LLC (“Healthstar”), pursuant to which the parties agreed to collaborate through a newly formed limited liability company structure.”
Wellgistics Health, Inc. entered into Collaboration Agreement with Kare Rx Hub, LLC, Kare Pharmtech, LLC, and Healthstar Technologies, LLC valued at $2,000,000 (effective 2026-04-13).
“On April 13, 2026, Wellgistics Health, Inc. (the “Company”) entered into a Collaboration Agreement (the “Collaboration Agreement”) with Kare Rx Hub, LLC (“Kare Hub”), Kare Pharmtech, LLC (“Kare Pharmtech”), and Healthstar Technologies, LLC (“Healthstar”), pursuant to which the parties agreed to collaborate through a newly formed limited liability company structure.”
Wellgistics Health, Inc. terminated Settlement Agreement with Silverback Capital Inc. (effective 2026-04-03).
“On April 3, 2026, Wellgistics Health, Inc. (the “Company”) delivered written notice to Silverback Capital Inc. terminating that certain Settlement Agreement and Stipulation, dated January 28, 2026 (the “Settlement Agreement”), previously entered into between the Company and Silverback Capital Inc.”
Wellgistics Health, Inc. incurred senior notes of up to $1,250,000 in aggregate principal amount with certain investors at 0% maturing the twelve (12) month anniversary of the date of issuance of the Notes, or (b) the date of closing of the next issuance and sale of capital stock of the Company.
“the Company agreed to issue and sell to the Investors in a private offering up to $1,250,000 in aggregate principal amount (the “Aggregate Principal Amount”) of promissory notes (the “Notes”) (the “Offering”).”
Wellgistics Health, Inc. entered into Note Purchase Agreement with certain investors valued at up to $1,250,000 in aggregate principal amount (effective 2026-04-01).
“On April 1, 2026, Wellgistics Health, Inc. (the “Company”), entered into a note purchase agreement (the “Note Purchase Agreement”) with certain investors (the “Investors”) whereby the Company agreed to issue and sell to the Investors in a private offering up to $1,250,000 in aggregate principal amount (the “Aggregate Principal Amount”) of promissory notes (the “Notes”) (the “Offering”).”
Wellgistics Health, Inc. entered into Interim Commercialization and Revenue Share Agreement with Kare PharmTech LLC (effective 2026-03-06).
“On March 6, 2026, Wellgistics Health, Inc. (the “Company”), entered into an Interim Commercialization and Revenue Share Agreement (the “Revenue Share Agreement”) with Kare PharmTech LLC”
Wellgistics Health, Inc. entered into Settlement Agreement and Stipulation with Silverback Capital Corporation valued at Settlement of aggregate principal amount of not less than $10,712,734.16 in liabilities via issuance (effective 2026-01-28).
“Previously, on January 28, 2026, the Company and SCC entered into a Settlement Agreement and Stipulation (the “Settlement Agreement”), pursuant to which SCC agreed to acquire and settle certain bona fide liabilities and obligations of the Company in an aggregate principal amount of not less than $10,712,734.16 (the “Claim Amount”) (the “Settlement”).”
Wellgistics Health, Inc. incurred convertible notes of up to $8,125,000 in aggregate principal amount with certain investors at 0% except in the event of an event of default, in which case, the default intere maturing the six (6) month anniversary of the date of issuance of the Notes, or the date of closing of the next issuance and sale of capital stock of the Company.
“On January 16, 2026, Wellgistics Health, Inc. (the “Company”), entered into a note purchase agreement (the “Note Purchase Agreement”) with certain investors (the “Investors”) whereby the Company agreed to issue and sell to the Investors in a private offering up to $8,125,000 in aggregate principal amount (the “Aggregate Principal Amount”) of secured convertible promissory notes (the “Notes”) (the “Offering”).”
Wellgistics Health, Inc. entered into Placement Agency Agreement with Dawson James Securities, Inc. (effective 2026-01-16).
“On January 16, 2026, in connection with the Offering, the Company entered into a placement agency agreement, a copy of which is filed as Exhibit 10.3 to this Current Report on Form 8-K (the “Placement Agency Agreement”) with Dawson James Securities, Inc. (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the Company’s placement agent in connection with the Offering.”
Wellgistics Health, Inc. entered into Note Purchase Agreement with certain investors valued at up to $8,125,000 in aggregate principal amount (effective 2026-01-16).
“On January 16, 2026, Wellgistics Health, Inc. (the “Company”), entered into a note purchase agreement (the “Note Purchase Agreement”) with certain investors (the “Investors”) whereby the Company agreed to issue and sell to the Investors in a private offering up to $8,125,000 in aggregate principal amount (the “Aggregate Principal Amount”) of secured convertible promissory notes (the “Notes”) (the “Offering”).”
Wellgistics Health, Inc. entered into Placement Agency Agreement with Dawson James Securities, Inc. (the “Placement Agent”) (effective 2026-01-05).
“On January 5, 2026, in connection with the Offering, the Company entered into a placement agency agreement, a copy of which is filed as Exhibit 10.3 to this Current Report on Form 8-K (the “Placement Agency Agreement”) with Dawson James Securities, Inc. (the “Placement Agent”), pursuant to which the Placement Agent agreed to act as the Company’s placement agent in connection with the Offering.”
Wellgistics Health, Inc. entered into Note Purchase Agreement with certain investors (the "Investors") valued at up to $3,125,000 in aggregate principal amount (effective 2026-01-05).
“On January 5, 2026, Wellgistics Health, Inc. (the “Company”), entered into a note purchase agreement (the “Note Purchase Agreement”) with certain investors (the “Investors”) whereby the Company agreed to issue and sell to the Investors in a private offering up to $3,125,000 in aggregate principal amount (the “Aggregate Principal Amount”) of convertible promissory notes (the “Notes”) (the “Offering”).”
Wellgistics Health, Inc. incurred convertible notes of up to $3,125,000 in aggregate principal amount with certain investors at 0% except in the event of an event of default, in which case, the default intere maturing on (a) the six (6) month anniversary of the date of issuance of the Notes, or (b) the date of closing of the next issuance and sale of capital stock of the Comp.
“On January 5, 2026, Wellgistics Health, Inc. (the “Company”), entered into a note purchase agreement (the “Note Purchase Agreement”) with certain investors (the “Investors”) whereby the Company agreed to issue and sell to the Investors in a private offering up to $3,125,000 in aggregate principal amount (the “Aggregate Principal Amount”) of convertible promissory notes (the “Notes”) (the “Offering”).”
Wellgistics Health, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“December 9, 2025, the common stock of the Company had not maintained a minimum closing bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until June 8, 2026 (the “Compliance Period”), to regain compliance with the Bid Price Rule. If the Company does not regain compliance with the Bid Price Rule by June 8, 2026, the Company may be eligible for an additional 180-day period to reg”
Wellgistics Health, Inc. engaged Suri & Co., Chartered Accountants as its auditor.
“On November 17, 2025, the Audit Committee of the Board of Directors approved the re-engagement of Suri & Co., Chartered Accountants (“Suri”), as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.”
UHY LLP resigned as auditor of Wellgistics Health, Inc..
“ormal notice that the Company’s independent auditors, UHY LLP (“UHY”), had made the decision to resign as the Company’s independent accountants effective November 11, 2025. UHY indicated that they have elected to resign in light of certain information identified in the resignation of the former Chief Executive Officer of the Company, which had not yet been investigated.”
Wellgistics Health, Inc. engaged UHY LLP as its auditor.
“On July 7, 2025, the Company's Board of Directors approved the engagement of UHY LLP ("UHY") as the Company's new independent registered public accounting firm, effective as of July 7, 2025.”
Wellgistics Health, Inc. dismissed Suri & Co., Chartered Accountants as its auditor.
“On July 7, 2025, the Board of Directors of Wellgistics Health, Inc. (the "Company") approved the dismissal of Suri & Co., Chartered Accountants ("Suri"), the Company's independent registered public accounting firm.”
Vishnu Balu departed as Chief Financial Officer at Wellgistics Health, Inc..
“Mr. Balu’s decision to resign is not the result of any dispute or disagreement with the Company, the Company’s management or the Company’s Board of Directors on any matter relating to the Company’s operations, policies or practices.”
Mark DiSiena was appointed as Chief Financial Officer at Wellgistics Health, Inc..
“On April 22, 2025, the Board of Directors of Wellgistics Health, Inc. (the “Company”) appointed Mark DiSiena as Chief Financial Officer of the Company, effective as of April 22, 2025”
Michael L. Peterson was appointed as Director at Wellgistics Health, Inc..
“the Board appointed Michael L. Peterson to fill the vacancy created as a result of Mr. Sayed’s departure.”
Sajid Sayed resigned as Director at Wellgistics Health, Inc..
“Sajid Sayed informed the Company’s board of directors of his intent to resign as a director of the Company, effective immediately.”
Timothy Canning departed as Chief Executive Officer at Wellgistics Health, Inc..
“Mr. Norton will succeed Timothy Canning, who served as the Company’s Chief Executive Officer since January 18, 2024, and who is resigning from his position, effective as of the Effective Date.”
Brian Norton was appointed as Chief Executive Officer at Wellgistics Health, Inc..
“promoted Brian Norton to serve as the Company’s Chief Executive Officer effective as of February 28, 2025”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.